A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin Adolescents and Children With Chronic HCV-Infection
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 17 Jul 2017 Planned number of patients changed from 200 to 220.
- 21 Apr 2017 According to a Gilead Sciences, results from this study were presented at The International Liver Congress 2017.
- 21 Apr 2017 Results published in the Gilead Sciences media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History